{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+2&page=2",
    "query": {
      "intervention": "Test Product 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T20:07:22.605Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01125553",
      "title": "A Comparison Between Two Formulations of NN5401 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "insulin degludec/insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2010-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-25",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125553"
    },
    {
      "nct_id": "NCT00276302",
      "title": "Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Soft Tissue Sarcomas"
      ],
      "interventions": [
        {
          "name": "IPI-504",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2005-12",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2011-01-06",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276302"
    },
    {
      "nct_id": "NCT05405595",
      "title": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ADG126",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (Trifluridine/Tipiracil-Bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Standard of care (Fruquintinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adagene Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2022-06-15",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405595"
    },
    {
      "nct_id": "NCT04771403",
      "title": "Two Way Crossover Closed Loop Study MPC vs FMPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "FMPD AP algorithm",
          "type": "DEVICE"
        },
        {
          "name": "MPC AP system",
          "type": "DEVICE"
        },
        {
          "name": "Dexcom G6 Continuous Glucose Monitoring (CGM) System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-02-23",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-17",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771403"
    },
    {
      "nct_id": "NCT05845645",
      "title": "A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants"
      ],
      "interventions": [
        {
          "name": "UCB0599",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 73,
      "start_date": "2023-05-31",
      "completion_date": "2024-04-13",
      "has_results": true,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05845645"
    },
    {
      "nct_id": "NCT00853736",
      "title": "Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Roxicodone™ tablet 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone hydrochloride tablet 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2003-02",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853736"
    },
    {
      "nct_id": "NCT05166694",
      "title": "Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Mental Health Issue",
        "Behavior Disorders"
      ],
      "interventions": [
        {
          "name": "Drug-Drug Interaction Profile",
          "type": "OTHER"
        },
        {
          "name": "Drug-Gene Interaction Profile",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1300,
      "start_date": "2022-11-30",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05166694"
    },
    {
      "nct_id": "NCT01894451",
      "title": "Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Inflammatory Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "89Zr-bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "FDG-PET/CT",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Tumor biopsies",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-06",
      "completion_date": "2017-03-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894451"
    },
    {
      "nct_id": "NCT07473752",
      "title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Phase 1 First-in-human Study Involving Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "TNX-1500",
          "type": "DRUG"
        },
        {
          "name": "Placebo: USP 0.9% sterile saline for injection",
          "type": "DRUG"
        },
        {
          "name": "Keyhole Limpet Hemocyanin (KLH)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-07-18",
      "completion_date": "2024-02-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07473752"
    },
    {
      "nct_id": "NCT05170425",
      "title": "LAMBDA 002 (Lung Registry) Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Prospera",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2022-11-04",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-09-22T20:07:22.605Z",
      "location_count": 11,
      "location_summary": "California City, California • Chicago, Illinois • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "California City",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05170425"
    }
  ]
}